This is a routine awareness-building disclosure with no immediate catalyst. Monitor for any subsequent clinical trial announcements or government funding related to Ebola preparedness, but do not trade on this filing alone.
Price Chart
Executive Summary
AIM ImmunoTech released a video presentation and investor slide deck discussing previously published preclinical data on Ampligen's potential as a prophylactic/early-onset treatment for Ebola virus disease (EVD). The filing contains no new financial data, no guidance, and no material operational changes—it is a routine Regulation FD disclosure of forward-looking scientific commentary.
Key Facts
- Filing is an 8-K under Item 7.01 (Reg FD Disclosure) and 9.01 (Exhibits).
- Company released a video segment and updated investor presentation on Ampligen's preclinical Ebola data.
- Preclinical data cited: 100% protective survival with early Ampligen administration in a lethal Ebola mouse model.
- Ampligen has orphan drug designation from both FDA and EMA for Ebola virus disease.
- No financial results, guidance, or material agreements were disclosed.
- Market cap is approximately $12M; the company is a pre-revenue clinical-stage biotech.
Financial Impact
No financial impact disclosed; filing is purely informational.
Risk Factors
- Preclinical results may not translate to human efficacy.
- Company has no approved products and limited cash runway (market cap ~$12M).
- No new funding or partnership announced to advance the Ebola program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027210 |
| Exhibit: ex99-1.htm | 0001493152-26-027210 |
| Document: 0001493152-26-027210-index-headers.html | 0001493152-26-027210 |
| Document: 0001493152-26-027210-index.html | 0001493152-26-027210 |
| Document: 0001493152-26-027210.txt | 0001493152-26-027210 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers